Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars

Vandana Singh
1 min read
0
In this article:

  • Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE in healthy volunteers.

  • ARO-RAGE is an investigational RNA interference (RNAi) therapeutic designed to reduce the production of the receptor for advanced glycation end products (RAGE) as a potential treatment for inflammatory pulmonary diseases, such as asthma.

  • Also Read: Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'

  • Reductions in soluble RAGE (sRAGE) as measured in serum after two doses on Day 1 and Day 29:

    • The mean maximum reduction at 92 mg dose was 80%, with a maximum reduction of 90%.

    • Mean maximum reductions at 10 to 44 mg doses showed a dose response ranging from 31% to 59%.

  • Reductions in serum sRAGE were also observed after a single dose:

    • The mean maximum reduction at 92 mg dose was 56%, with a maximum reduction of 68%.

  • Overall, no patterns of adverse changes in any clinical safety parameters were observed.

  • There were no reported serious or severe adverse events.

  • Also, there were no dropouts related to the drug or related to adverse events.

  • Price Action: ARWR shares are up 13.70% at $34.14 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories